Persistence Targeted Smoking Cessation in Schizophrenia

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will conduct a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rutgers, The State University of New Jersey
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Nicotine

Criteria

Inclusion Criteria:

• Must be between 18 - 70 years old

• Must indicate willingness to make a quit attempt in the next 30 days

• Must smoke at least 5 cigarettes (including those labeled "little cigars") per day for past month

• Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use

• Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview (SCID-5)

• Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks

Exclusion Criteria:

• Must not currently (in past 10 days) be taking varenicline (Chantix),

• Must not currently (in past 10 days) be taking bupropion (Zyban/Wellbutrin) to quit smoking.

• Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days

• Must not report myocardial infarction, unstable angina pectoris, or significant cardiac arrhythmia (including atrial fibrillation) in the past 30 days.

• Women must not be pregnant, "test positive" on a pregnancy test, nursing, or planning on becoming pregnant in the next three months. Women who can become pregnant may be included if using effective birth control.

• Must not have pending legal matters with potential to result in jail time

• Must not be planning on moving outside local area in next 3-months